Table 2.
Results of the test of proportionality of the hazards* for different treatment groups by dataset and endpoint
| Trial | P | ||||
|---|---|---|---|---|---|
| Survival | Disease-free survival | Recurrence | Local-regional recurrence | Distant recurrence | |
| B-05 | .86 | .05 | .01 | .06 | .16 |
| B-07 | .17 | .52 | .35 | .29 | .10 |
| B-08 | .55 | .40 | .23 | .08 | .73 |
| B-09† | .67 | .03 | .11 | .16 | .47 |
| B-10 | .23 | .32 | .33 | .61 | .10 |
| B-11 | 1.00 | <.01 | .04 | .04 | .49 |
| B-12 | .02 | .12 | .07 | .13 | .33 |
| B-13 | .83 | .34 | .87 | .32 | .33 |
| B-14 | .23 | <.01 | .01 | <.01 | .12 |
| B-15† | .78 | .96 | .51 | .70 | .43 |
| B-16† | .04 | .02 | .09 | .25 | .25 |
| B-19 | .31 | .10 | .34 | .54 | .21 |
| B-20 | .77 | .21 | .18 | .03 | .47 |
| B-22† | .89 | .81 | .98 | .55 | .63 |
| B-23 | .17 | <.01 | .01 | <.01 | .42 |
| B-25† | .28 | .89 | .20 | .08 | .80 |
| B-28† | .36 | .71 | .84 | .72 | .60 |
| B-30† | .38 | .30 | .15 | .71 | .13 |
| B-31† | .85 | .53 | .38 | .19 | .03 |
* Tested the statistical significance of the presence of interaction between treatment and ln(time). Two-sided P values less than or equal to .05 were considered statistically significant.
† Using the stratified-by-receptor-status Cox regression model.